Headquartered in Laval, QC Fiscal year ends December NYSE: BHC bauschhealth.com
Bausch Health Companies Inc. is a diversified global pharmaceutical company. It develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health.
Its reporting segments are:
- **Salix:** Gastroenterology and hepatology, anchored by Xifaxan.
- **International:** Branded pharmaceuticals outside the U.S., led by Canada.
- **Solta Medical:** Aesthetic medical devices, recently expanded through the acquisition of its full-service distributor in China.
- **Diversified:** Neuroscience, dermatology, generics and dentistry.
- **Bausch + Lomb:** Eye health, comprising Vision Care, Surgical and Pharmaceuticals. Bausch Health holds a controlling interest in this publicly listed company.
The company is highly leveraged, with about $20.2 billion of debt obligations, and has been refinancing and paying down debt. It continues to evaluate strategic options to unlock shareholder value from its Bausch Health and Bausch + Lomb assets, including a potential separation of the eye health business. Its CEO also serves as Chairman and interim CEO of Bausch + Lomb. Shares trade on the NYSE and TSX under BHC. Updated
Management cut net debt by more than $500 million in the quarter, the number that matters most against roughly $20 billion of debt on a $2.6 billion market cap. Earnings came in 42% above expectations with a raised full-year outlook, and Xifaxan grew 16% ahead of its 2027 Medicare negotiated price.
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
Dan Loeb of Third Point is a brilliant investor worth watching closely whenever the 13F filings roll in. He’s a billionaire activist investor who seems to know how to spot value in…
One insider scooped up many shares as Carl Icahn exited his stake in a medical device maker. There were other notable insider purchases too.
One of the best ways to spot a potential opportunity is by tracking insiders. After all, who knows the company better than an insider – the CEO, CFO, COO, officers, employees, and…
In the past week, a couple of gold-mining stocks attracted the attention of insider buyers. Billionaire hedge fund manager John Paulson was a huge insider buyer this past week.
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
Bausch Health Companies Inc. is a diversified global pharmaceutical company. It develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health.
24/7 Wall St.'s 12-month price target for BHC is $9.93, rated Buy. The Wall Street consensus target is $8.00. BHC price prediction →
